# News · Salspera

Canonical: https://salspera.com/news/

Salspera in the news. A phase 2 study of orally administered live biotherapeutic Salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer

Salspera in the news.

## Featured · 2026

### A phase 2 study of orally administered live biotherapeutic Salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer

Batist G, Kavan P, Augustin L, Schottel J, Moradian J, Lee JT, Saltzman D · Cancer Immunology, Immunotherapy 2026;75(2):60

[Read the paper ↗](https://doi.org/10.1007/s00262-026-04307-0)

## Publications and presentations

- 2026 · [A Very Lucky Man: a retired urologist's three years on FOLFIRINOX and Saltikva under compassionate use](https://letswinpc.org/survivor-stories/very-lucky-clinical-trial/) · Heller J · Let's Win Pancreatic Cancer, Survivor Stories, 15 October 2026 (Article)
- 2026 · [Special delivery: bacterial couriers are smuggling drugs into cancers](https://doi.org/10.1038/d41586-026-02657-4) · Drew L · Nature 2026;657:S10–S12 · Nature Outlook, published 9 September 2026 (Article)
- 2026 · [Live Biotherapeutic Salmonella-IL2 (Saltikva) Plus FOLFIRINOX for Stage IV Metastatic Pancreatic Ductal Adenocarcinoma – Implications of a Phase 2 Clinical Trial](https://www.scientificarchives.com/article/live-biotherapeutic-salmonella-il2-saltikva-plus-folfirinox-for-stag-metastatic-pancreatic-ductal-adenocarcinoma-implications-of-a-phase-2-clinical-trial) · Saltzman DA, Kavan P, Augustin L, Schottel J, Lee JT, Moradian J, Moradian E, Batist G · Journal of Cellular Immunology 2026;8(2):37–47 (Paper)
- 2026 · [Suppression of New Metastases with Saltikva in a Phase II Clinical Trial: A Potential Signal of Immune Memory in Metastatic Pancreatic Ductal Adenocarcinoma](https://www.scientificarchives.com/journal/journal-of-cellular-immunology) · Batist G, Moradian J, Moradian E, Saltzman DA · Journal of Cellular Immunology 2026;8(2):48–52 (Paper)
- 2026 · [A phase 2 study of orally administered live biotherapeutic Salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer](https://doi.org/10.1007/s00262-026-04307-0) · Batist G, Kavan P, Augustin L, Schottel J, Moradian J, Lee JT, Saltzman D · Cancer Immunology, Immunotherapy 2026;75(2):60 (Paper)
- 2025 · [FDA Orphan Drug Designation for Saltikva® for the treatment of osteosarcoma](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1107925) · U.S. FDA Office of Orphan Products Development · designated 19 November 2025 (FDA)
- 2025 · [Influence of Salmonella-IL2 in combination with FOLFIRINOX on overall and progression-free survival in stage IV metastatic pancreatic cancer](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.2571) · Saltzman D, Kavan P, Augustin L, Schottel J, Lee JT, Moradian J, Moradian E, Batist G · Journal of Clinical Oncology 2025;43(16_suppl):2571 · ASCO Annual Meeting (Abstract)
- 2025 · [The emerging landscape of engineered bacteria cancer therapies](https://doi.org/10.1038/s41587-025-02623-x) · Ballister ER, Michels A, Vincent RL, Kreindler L, Chowdhury S, Upadhaya S, Saez-Ibañez AR, Tu T, Gottweis J, Danino T · Nature Biotechnology 2025 (Paper)
- 2023 · [AACR Annual Meeting 2023: conference news featuring Salmonella-IL2 plus FOLFIRINOX in stage IV pancreatic cancer](https://doi.org/10.1016/S1470-2045(23)00179-1) · Reeves C · The Lancet Oncology, published online 20 April 2023 (Article)
- 2023 · [Abstract CT035: Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival](https://doi.org/10.1158/1538-7445.AM2023-CT035) · Kavan P, Saltzman D, Moradian J, Muegge J, Batist G · Cancer Research 2023;83(8_Suppl):CT035 · AACR Annual Meeting (Abstract)
- 2022 · FDA Fast Track designation for Saltikva® in combination with FOLFIRINOX to improve overall survival in metastatic pancreatic cancer · U.S. FDA, grant of Fast Track designation · 2022 (FDA)
- 2022 · [FDA Orphan Drug Designation for Saltikva® for the treatment of pancreatic cancer](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=877922) · U.S. FDA Office of Orphan Products Development · designated 17 May 2022 (FDA)
- 2020 · [Orally Administered Multiple Dose Saltikva (Salmonella-IL2) in Conjunction with FOLFIRINOX in a Patient with Stage IV Pancreatic Cancer: A Case Report](https://www.scitechnol.com/peer-review/orally-administered-multiple-dose-saltikva-salmonellail2-in-conjunction-with-folfirinox-in-a-patient-with-stage-iv-pancreatic-canc-bFNn.php?article_id=11055) · Batist G, Park J, et al. · Clinical Oncology: Case Reports 2020 (Paper)
- 2018 · [White paper on microbial anti-cancer therapy and prevention](https://doi.org/10.1186/s40425-018-0381-3) · Forbes NS, Coffin RS, Deng L, … Moradian E, … Saltzman DA, et al. · Journal for ImmunoTherapy of Cancer 2018;6:78 (Paper)
- 2016 · [A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma](https://doi.org/10.1002/vms3.32) · Fritz SE, Henson MS, Greengard E, … Modiano JF, Saltzman DA · Veterinary Medicine and Science 2016;2(3):179–190 (Paper)
- 2015 · [Attenuated Salmonella enterica Typhimurium Reduces Tumor Burden in an Autochthonous Breast Cancer Model](https://ar.iiarjournals.org/content/35/2/843) · Drees JJ, Mertensotto MJ, Liu G, Panyam J, Leonard AS, Augustin LB, Schottel JL, Saltzman DA · Anticancer Research 2015;35(2):843–850 (Paper)
- 2011 · [Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis](https://doi.org/10.2147/OTT.S17081) · Sorenson BS, Banton KL, Augustin LB, Leonard AS, Saltzman DA · OncoTargets and Therapy 2011;4:53–61 (Paper)
- 2010 · [Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model](https://doi.org/10.2147/BTT.S9121) · Sorenson BS, Banton KL, Frykman NL, Leonard AS, Saltzman DA · Biologics: Targets & Therapy 2010;4:61–73 (Paper)
- 2008 · [Attenuated Salmonella typhimurium with IL-2 Gene Reduces Pulmonary Metastases in Murine Osteosarcoma](https://doi.org/10.1007/s11999-008-0243-2) · Sorenson BS, Banton KL, Frykman NL, Leonard AS, Saltzman DA · Clinical Orthopaedics and Related Research 2008;466(6):1285–1291 (Paper)
- 2008 · [Attenuated Salmonella typhimurium with interleukin 2 gene prevents the establishment of pulmonary metastases in a model of osteosarcoma](https://doi.org/10.1016/j.jpedsurg.2008.02.048) · Sorenson BS, Banton KL, Frykman NL, Leonard AS, Saltzman DA · Journal of Pediatric Surgery 2008;43(6):1153–1158 (Paper)
- 2003 · [Attenuated Salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model](https://pubmed.ncbi.nlm.nih.gov/12861543/) · Soto LJ III, Sorenson BS, Kim AS, Feltis BA, Leonard AS, Saltzman DA · Journal of Pediatric Surgery 2003;38(7):1075–1081 (Paper)
- 2002 · [Liver and Circulating NK1.1⁺CD3⁻ Cells Are Increased in Infection with Attenuated Salmonella typhimurium and Are Associated with Reduced Tumor in Murine Liver Cancer](https://doi.org/10.1006/jsre.2002.6428) · Feltis BA, Miller JS, Sahar DA, Kim AS, Saltzman DA, Leonard AS, Wells CL, Sielaff TD · Journal of Surgical Research 2002;107(1):101–107 (Paper)
- 2002 · [Cyclooxygenase-2 Inhibition Augments the Hepatic Antitumor Effect of Oral Salmonella Typhimurium in a Model of Mouse Metastatic Colon Cancer](https://pubmed.ncbi.nlm.nih.gov/12195185/) · Feltis BA, Sahar DA, Kim AS, Saltzman DA, Leonard AS, Sielaff TD · Journal of Gastrointestinal Surgery 2002 (Paper)
- 1996 · [Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: A novel antitumor agent?](https://pubmed.ncbi.nlm.nih.gov/9044141/) · Saltzman DA, Katsanis E, Heise CP, Hasz DE, Vigdorovich V, Kelly SM, Curtiss R III, Leonard AS, Anderson PM · Journal of Pediatric Surgery 1996;31(2):301–306 (Paper)
- 1996 · [Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: A novel anti-tumor agent](https://doi.org/10.1089/cbr.1996.11.145) · Saltzman DA, Heise CP, Hasz DE, Zebede M, Kelly SM, Curtiss R III, Leonard AS, Anderson PM · Cancer Biotherapy & Radiopharmaceuticals 1996;11(2):145–153 (Paper)

## Media contact

[Contact us →](https://salspera.com/contact/)

Logo and headshot files available on request.